Choosing the Right Formulation in Schizophrenia Treatment

In "Choosing the Right Formulation in Schizophrenia Treatment," our panel explores the practical decision-making process behind antipsychotic formulation selection, with Mark Jankelow sharing insights drawn from years of real-world clinical experience.

Mark Jankelow opens by acknowledging a common clinical reality: most patients presenting to outpatient practice have already received a prior diagnosis or been started on medication, making a truly first-episode presentation relatively rare in his experience. He underscores the importance of arriving at an accurate differential diagnosis, noting that patients often do not disclose psychotic symptoms — such as auditory hallucinations or paranoid ideation — until they have developed sufficient trust with their clinician, sometimes years into treatment. This delayed disclosure can lead to initial misdiagnosis as a mood disorder, with patients placed on mood stabilizers before the psychotic dimension of their illness becomes apparent.

When initiating treatment, Mark Jankelow describes a common clinical approach of starting with an oral second-generation or newer antipsychotic, in part because these agents offer the dual benefit of mood stabilization alongside antipsychotic coverage — providing a degree of protection even in diagnostically ambiguous cases. He candidly acknowledges the tendency among clinicians to default to oral formulations out of habit, while recognizing that transitioning to a long-acting injectable becomes a priority when adherence risk is identified. He highlights the pharmacokinetic vulnerability of short half-life oral agents, where even a few missed doses can result in rapid deterioration, and closes with a strong endorsement of long-acting injectables as an underutilized but highly valuable tool in this patient population.

Our next episode, "Empowering Patients and Expanding Formulation Options in Schizophrenia Care," examines the critical role of patient empowerment and shared decision-making in formulation selection, highlighting the barriers that prevent clinicians from fully communicating available treatment options and the importance of flexibility, collaboration, and a hopeful, patient-centered approach to schizophrenia management.